Key result
Anaemia is a common complication of congestive heart failure that worsens prognosis, and while intravenous iron improves symptoms, erythropoiesis-stimulating agents do not improve overall mortality.
This review highlights that while intravenous iron provides symptomatic benefit for iron-deficient heart failure patients, erythropoiesis-stimulating agents lack a clear mortality benefit and require cautious use.
Cautions against routine ESA use for mortality benefit in anaemic HF; leaves open optimized management strategies.
Anaemia is common in patients with congestive heart failure, and has an adverse effect on prognosis. This article discusses the advances in understanding of the pathophysiology of the anaemia, the treatment options including transfusion, and highlights areas in need of further development.
No takes yet. Share an insight, caveat, or question.
Eyre et al. (2013) conducted a review in Anaemia in congestive heart failure. Anaemia is a common complication of congestive heart failure that worsens prognosis, and while intravenous iron improves symptoms, erythropoiesis-stimulating agents do not improve overall mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: